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Materials and Methods 
Study subjects 
Donors were recruited from the Boston community as part of the Phenogenetic Project 
and ImmVar Consortium, and gave written informed consent for the studies. Individuals 
were excluded if they had a history of inflammatory disease, autoimmune disease, 
chronic metabolic disorders or chronic infectious disorders. For the microarray study, 30 
healthy human donors were recruited. Donors were between 19 and 49 years of age; 15 
were male and 15 were female; 18 were Caucasian, 6 were African-American and 6 were 
Asian; 12 provided a serial replicate blood sample (i.e. separate blood draw 2-9 months 
after the first collection). For the Nanostring study, 534 healthy donors were recruited, 37 
of whom came in multiple times providing additional serial replicates (i.e. separate blood 
draw > 1 month later). Donors were between 18 and 56 years of age (avg. 29.9); 
demographics are listed in table S1.  
 
Reagents 
LPS (ultrapure lipopolysaccharide from E. coli K12) was obtained from Invivogen (San 
Diego, CA). Influenza A (PR8 ΔNS1) was prepared as described (46). Recombinant 
human IFNβ was obtained from PBL Assay Science (Piscataway, NJ). Antibodies used 
were anti-IRF1 (sc-497x; Santa Cruz Biotechnology; Dallas, TX), anti-STAT2 (sc-476x; 
Santa Cruz Biotechnology) and anti-IRF9 (sc-10793x; Santa Cruz Biotechnology). 
 
Preparation and stimulation of primary human monocyte-derived dendritic cells 
35-50 mL of peripheral blood from fasting subjects was collected between 7:30-8:30 am. 
The blood was drawn into sodium heparin tubes and peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll-Paque (GE Healthcare Life Sciences; Uppsala, Sweden) 
centrifugation. PBMCs were frozen in liquid N2 in 90% FBS (Sigma-Aldrich; St. Louis, 
MO) and 10% DMSO (Sigma-Aldrich). Monocytes were isolated from PBMCs by 
negative selection using the Dynabeads Untouched Human Monocytes kit (Life 
Technologies; Carlsbad, CA) modified to increase throughput and optimize recovery and 
purity of CD14+CD16lo monocytes: the FcR Blocking Reagent was replaced with 
Miltenyi FcR Blocking Reagent (Miltenyi; Bergisch Gladbach, Germany); per mL of 
Antibody Mix, an additional 333 ug biotinylated anti-CD16 (3G8), 167 ug biotinylated 
anti-CD3 (SK7) and 167 ug biotinylated anti-CD19 (HIB19) antibodies (Biolegend; San 
Diego, CA) were added; the antibody labeling was modified to be performed in 96-well 
plates; and Miltenyi MS Columns or Multi-96 Columns (Miltenyi) were used to separate 
magnetically-labeled cells from unlabeled cells in an OctoMACS Separator or 
MultiMACS M96 Separator (Miltenyi) respectively. The number of PBMCs and 
monocytes was estimated using CellTiter-Glo Luminescent Cell Viability Assay 
(Promega; Madison, WI). A subset of the isolated monocytes was stained with PE-
labeled anti-CD14 (M5E2; BD Biosciences; Franklin Lakes, NJ) and FITC-labeled anti-
CD16 (3G8; Biolegend), and subjected to flow cytometry analysis using an Accuri C6 
Flow Cytometer (BD Biosciences). A median of 94% CD14+ cells and 99% CD16lo cells 
was obtained. The remaining monocytes were cultured for seven days in RPMI (Life 
Technologies) supplemented with 10% FBS, 100 ng/mL GM-CSF (R&D Systems; 





into monocyte-derived dendritic cells (MoDCs). 4x104 MoDCs were seeded in each well 
of a 96-well plate, and stimulated with 15 ng/mL LPS for 5 h, influenza virus for 10 h, 
100 U/mL IFNβ for 6.5 h or left unstimulated for up to 4 conditions per donor depending 
on available cell number. Cells were then lysed in RLT buffer (Qiagen; Hilden, 
Germany) supplemented with 1% β-mercaptoethanol (Sigma-Aldrich).  
 
Microarray gene expression profiling 
Total RNA was isolated from MoDCs using the RNeasy Mini kit (Qiagen). RNA 
quantification and quality were assessed using Agilent 2100 Bioanalyzer (Agilent 
Technologies; Santa Clara, CA). The cDNA synthesis, labeling and subsequent 
hybridization to the microarrays were performed by the company Expression Analysis 
(Durham, NC). Affymetrix Human Gene 1.0 ST arrays (Affymetrix; Santa Clara, CA) 
were used to obtain genome-wide expression profiles. 
 
Normalization of microarray data, adjustment for confounding effects and differential 
expression analysis 
Outlier detection was first performed. The dataset was then normalized using quantile 
normalization as part of the RMA pipeline. Expression > log2(80) was used as a filter 
resulting in 16,514 of 26,982 annotated transcripts. To eliminate possible confounding 
effects – in particular the batch effect from running arrays over two plates – surrogate 
variable analysis (SVA) was used to identify 13 permutation-significant surrogate 
variables (SVs) while controlling for known covariates for stimulation, population, 
gender and race. These SVs were used for subsequent analysis. K-means clustering was 
used to group the SVA-adjusted data into four distinct clusters corresponding to genes 
up-regulated in one or both of the conditions and a set of genes that were down-regulated. 
The number of differentially expressed transcripts per condition was computed using an 
Empirical Bayes model that included the SVs as covariates. Significance of differential 
expression was assessed by FDR (0.01) and log2(fold change) restrictions (> 0.75 or < –
1.5). Bonferroni adjusted binomial P-values for over-representation of Gene Ontology 
pathways were reported. 
 
Mixed model estimate of inter-individual and inter-population variable genes 
A linear mixed model was used to model the variance components for the expression of a 
gene i in individual j as: 𝑦!" = 𝛽! + 𝛽!Sex+ 𝛽!Age+ 𝛽!Population+ 𝜌!𝑃𝐶!!!!! + 𝑢! + 𝜖!" 
 
where 𝑉𝑎𝑟(𝒖)~𝜎!"#$%! 𝐾 and 𝑉𝑎𝑟(𝝐)~𝜎!!𝐼, K is a 𝑁×𝑁 matrix whose entry is 1 if two 
samples are the same individual. The above model was tested using a likelihood ratio test 
for inter-individual variability (𝜎!"#$%! = 0) as well as population specific genes (𝛽! = 0). 
Each condition (baseline, LPS, FLU, IFNβ and the respective responses) was analyzed 
separately. For each test, permutation based P-values were computed by randomly 
shuffling the individual labels 200 times and recalculating the likelihood ratio statistic. 






Selection of gene signature 
Normalization controls were selected by choosing genes with low variance in expression 
in the microarray data. Additional low variance controls were selected by choosing genes 
with low variance in response to LPS or influenza stimulations. Genes not known to be 
expressed in MoDCs including CD3, CD19, CD56 and CD235a were added as controls 
for contaminated cell types. Sex-specific genes from the Y-chromosome including 
DDX3Y, EIF1AY and ZFY were added for sample QC. Positive controls that represented 
genes with known cis-eQTLs were selected from baseline monocyte cis-eQTL data (47) 
and baseline MoDC cis-eQTL data (48). Known pathway components were selected from 
Ingenuity Pathway Analysis and references including (49-52). To capture inter-individual 
variation, genes with a log2(fold change) > 0.75 or log2(fold change) < –1.5, and with an 
inter- vs. intra-individual FDR < 0.1 in (i) LPS-induced expression values, (ii) influenza-
induced expression values, (iii) LPS response values and (iv) influenza response values 
were selected. To capture variation in population, genes with a log2(fold change) greater 
than 0.5 or less than –1.5, and with an inter- vs. intra-population FDR < 0.1 in LPS 
response values and influenza response values were selected. Genes with a maximum 
value of log2 > 13 across the microarray dataset were excluded to prevent saturation. 
Probes that excluded common SNPs (MAF > 5% from 1000 Genomes) were chosen, 
except for 11 genes for which this was not possible (table S3). The ability of the signature 
gene set to predict the genome-wide expression profile was measured using a structured 
regression model that imposes sparsity constraints as implemented in the PSI (53) 
package for expression imputation. 
 
Nanostring gene expression profiling and data normalization 
The Nanostring nCounter system (Nanostring; Seattle, WA) was used to digitally count 
transcripts in a multiplex reaction as previously described (54). Lysates in RLT buffer 
were hybridized for 12-24 hours with custom nCounter Gene Expression CodeSets. 
Quantification of hybridized RNA was performed using the nCounter Analysis System. 
To normalize the nCounter data, each sample was first normalized using the internal 
positive spike-in controls; the data was then normalized based on the average expression 
level of the low variance control genes. The per sample dispersion parameter was 
estimated as previously described (55) and the data was variance-stabilized for further 
processing. 
 
DNA extraction and genotyping 
Genomic DNA was extracted from 5 mL whole blood (DNeasy Blood & Tissue Kit; 
Qiagen), and quantified by NanoDrop (Thermo Fisher Scientific; Waltham, MA). Each 
subject was genotyped using the Illumina Infinium Human OmniExpress and Human 
Exome BeadChips (Illumina; San Diego, CA), which includes genome-wide genotype 
data as well as genotypes for rare variants from 12,000 exomes as well as common 
coding variants from the whole genome. In total, 951,117 SNPs were genotyped, of 
which 704,808 SNPs are common variants (Minor Allele Frequency (MAF) > 0.01) and 
246,229 are part of the exomes. The genotype success rate was greater than or equal to 
97%. We applied rigorous subject and SNP quality control (QC) that includes (1) gender 
mis-identification, (2) subject relatedness, (3) Hardy-Weinberg Equilibrium testing, (4) 





and (7) subject mismatches. In the European population, we excluded 1,987 SNPs with a 
call rate < 95%, 459 SNPs with Hardy-Weinberg equilibrium P-value < 10–6, 234 SNPs 
with a MisHap P-value < 10–9, and 63,781 SNPs with MAF < 1% (a total of 66,461 SNPs 
excluded). In the African-American population, we excluded 2,161 SNPs with a call rate 
< 95%, 298 SNPs with Hardy-Weinberg equilibrium P-value < 10–6, 50 SNPs with a 
MisHap P-value < 10–9, and 17,927 SNPs with MAF < 1% (a total of 20,436 SNPs 
excluded). In the East Asian population, we excluded 1,831 SNPs with a call rate < 95%, 
213 SNPs with Hardy-Weinberg equilibrium P-value < 10–6, 47 SNPs with a MisHap P-
value < 10–9, and 84,973 SNPs with MAF < 1% (a total of 87,064 SNPs excluded). After 
QC, 52 subjects across all three populations and approximately 18,000-88,000 SNPs in 
each population were filtered out from our analysis. 
 
Population stratification: Underlying genetic stratification in the population was assessed 
by multi-dimensional scaling using data from the International HapMap Project (CEU, 
YRI and CHB samples) combined with IBS cluster analysis using the Eigenstrat 3.0 
software (56).  
 
The quality control of the genotyping data were performed using PLINK (57). 
 
Pooled condition-specific eQTL mapping 
Using only typed SNPs, we performed eQTL mapping by pooling all individuals across 
three populations together for each of the four conditions (baseline, LPS, FLU and IFNβ) 
and the corresponding fold change (LPS/baseline, FLU/baseline and IFNβ/baseline). We 
included gender, age and population as known covariates and significant principal 
components (determined by permutation) to account for unknown confounding effects in 
the following linear model: 𝑦!" = 𝛽! + 𝛽!SNP+ 𝛽!Sex+ 𝛽!Age+ 𝛽!Pop+ 𝜌!𝑃𝐶!!!!! +𝜖!" 
 
We estimated the parameter 𝛽! and its corresponding standard error for each gene-SNP 
pair in each condition. We computed a likelihood ratio statistic comparing 𝛽! to the null 
hypothesis of 𝛽! = 0. All mapping were performed using a modified version of Matrix 
eQTL (58). 
 
For cis-eQTLs, we computed experiment-wise significance for the best eQTL detected 
per gene by permuting the labels of individuals 200 times and computing the FDR by 
comparing the distribution of P-values to the empirical null using the qvalue package 
(59). We used random effects meta-analysis that accounts for effects size heterogeneity 
between conditions and the M-value (60) to categorize genes into specific patterns of 
association. A cis-eQTL is categorized to be specific to a particular condition if its M-
value in the condition is > 0.9. For cis-reQTL, a conservative exclusion criteria of M-
value < 0.1 was additionally used. In addition, a reQTL was required in one condition. 
 
For trans-eQTLs, we considered all variants as well as only cis-variants to genes on our 
codeset to limit the number of multiple tests performed. To detect additional independent 





covariates in the regression model. For all of these tests, we assessed experiment-wise 
significance for the best trans-eQTL detected or best secondary cis-eQTL per gene by 
permuting the labels of individuals 200 times and computing the FDR by comparing the 
distribution of P-values to the empirical null using the qvalue package. 
 
Genotype imputation 
To accurately evaluate the evidence of association signal at variants that are not directly 
genotyped, we used the BEAGLE software (version: 3.3.2) (61) to impute the post-QC 
genotyped markers using reference Haplotype panels from the 1000 Genomes Project 
(The 1000 Genomes Project Consortium Phase I Integrated Release Version 3), which 
contain a total of 37.9 million SNPs in 1,092 individuals with ancestry from West Africa, 
East Asia and Europe. For subjects of European and East Asian ancestry, we used 
haplotypes from Utah residents (CEPH) with Northern and Western European ancestry 
(CEU), and combined panels from Han Chinese in Beijing (CHB) and Japanese in Tokyo 
(JPT), respectively. For imputing African-American subjects, we used a combined 
haplotype reference panels consisting of CEU and Yoruba in Ibadan, Nigeria (YRI). 
After genotype imputation, we filtered out poorly imputed (BEAGLE 𝑟! < 0.1) and low 
MAF SNPs (MAF < 0.01), which resulted in 7.7M, 6.6M, 12.7M common variants in 
European, East Asian and African-American, respectively. This set of genotyped and 
imputed markers was used for all the subsequent association analysis. 
 
Population-specific eQTL mapping using imputed SNPs for fine-mapping 
To increase the power to detect functional variants, we performed fine-mapping using 
imputed SNPs in each population (Asian, African-American and Caucasian) and 
condition (baseline, LPS, FLU, IFNβ, LPS/baseline, FLU/baseline and IFNβ/baseline) 
separately using the following linear model that includes significant principal 
components estimated in each population/condition separately: 𝑦!" = 𝛽! + 𝛽!SNP+ 𝛽!Sex+ 𝛽!Age+ 𝜌!𝑃𝐶!!!!! +𝜖!" 
 
We estimated the parameter 𝛽! and its corresponding standard error for each gene-SNP 
pair in each population/condition. For each condition, we used mixed effects meta-
analysis (60) that accounts for differing linkage disequilibrium patterns in each 
population (based on dense imputed data from 10M SNPs using the 1,000 Genomes 
Project dataset (62)) and the assumption of shared causal alleles (63) (using a random 
effects meta-analysis (60) on the imputed cis-reQTLs from the three populations). Next, 
we searched for associated variants (at each locus) that alter TF binding elements in these 
regions to detect variants with shared effects across the three populations, hypothesizing 
that these might be enriched for functional variants in the absence of epistasis. 
 
ChIP-Seq enrichment 
SNPs intersected with human ChIP-seq peaks from ENCODE (64) were obtained from 
HaploReg (65). Mouse ChIP-seq data were obtained from (66) and the liftOver tool was 
used (with parameters -minMatch=0.1 and -multiple) on the mouse peaks to find 
orthologous regions between mouse genome version mm9 and human genome version 






For each ChIP annotation, the overlap with the top five eQTLs for each gene was 
compared to the frequency of the ChIP annotation among a background set of all 1000 
Genomes Project Phase 1 SNPs (68) with frequency greater than 5% in at least one 
population within 1 Mb of the start and end of assayed genes. Enrichment relative to 
background was evaluated using a binomial test. 
 
Allelic imbalance 
Total RNA was extracted using the RNeasy Mini kit (Qiagen) from MoDC lysates from 
individuals heterozygous for selected exonic SNPs as well as for the most significant cis-
eQTL SNP in LD. cDNA was synthesized using High Capacity cDNA Reverse 
Transcription kit (Life Technologies). TaqMan genotyping assays (Life Technologies) 
that discriminate between the two exonic alleles were designed and performed on the 
cDNA and corresponding genomic DNA (gDNA) samples using the LightCycler 480 
system (Roche; Basel, Switzerland). Ratio of alleles in the cDNA was normalized to the 
ratio of alleles in the gDNA. Amplification primers for SLFN5: 5'-
CGTTTTCTCTTGCGGAATGGT-3' and 5'-TCATTGCTGTTAGAAGCCTGTCTTT-3'; 
reporter primers for SLFN5: 5'-CAATATCCTTCGGAGAATA-3' (VIC) and 5'-
CAATATCCTTCAGAGAATA-3' (FAM). Amplification primers for CLEC4F: 5'-
CATCACCACTTTGGCAGGGA-3' and 5'-CCATGTGGCCTTTAAATGTCTGGAT-3'; 




Constructs encoding human IRF7 or eGFP control cDNA were nucleofected into MoDCs 
using Amaxa Human Dendritic Cell Nucleofector Kit (Lonza; Basel, Switzerland). 18 h 
later, cells were infected with influenza and then lysed 10 h post-infection in RLT buffer 
(Qiagen) supplemented with 1% β-mercaptoethanol. Constructs encoding human IRF7 or 
eGFP control cDNA were also transfected into HEK-293 cells using TransIT-LT1 
(Mirus; Madison, WI). Cells were lysed 22 h later in RLT buffer supplemented with 1% 
β-mercaptoethanol. 
 
Luciferase reporter assays 
The major haplotypes of SLFN5 (192 bp; chr17:33,571,450-33,571,641), CLEC4F (159 
bp; chr2:71,050,488-71,050,646) and ARL5B (199 bp; chr10:18,947,302-18,947,500) 
were cloned 5’ of the minimal promoter in the firefly luciferase reporter vector pGL4.23 
(Promega). Minor allele SNPs were introduced using the QuikChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies). Constructs were co-transfected with 
the Renilla luciferase control vector pRL-CMV (Promega) into HEK293T cells using 
TransIT-LT1 (Mirus). 8 h later, cells were stimulated with 1000 U/mL recombinant IFNβ 
for 21 h, and then firefly and Renilla luciferase activities were measured using Dual-Glo 
Luciferase Assay System (Promega).  
 
Gel shift assays 
Nuclear extracts were prepared (NE-PER; Thermo Fisher Scientific) from MoDCs 





IA) were labeled with [γ32 P]-ATP using T4 polynucleotide kinase (NEB; Ipswich, MA), 
and annealed with the reverse complementary oligos. Sequences used were as follows: 
ISRE control (5’-AAGTACTTTCAGTTTCATATTACTCTA-3’; Santa Cruz 
Biotechnology), ISRE mutant (5’-AAGTACTTTCAGTGGTCTATTACTCTA-3’; Santa 
Cruz Biotechnology), CLEC4F major (5’-TGTCTTGGTTTCTGTTTCCCCATAC-3’; 
chr2:71,050,550-71,050,574), CLEC4F minor (5’-
TGTCTTGGTTTATGTTTCCCCATAC-3’; chr2:71,050,550-71,050,574), ARL5B major 
(5’-GACATTCAGTTTCGTTTCATGCCAG-3’; chr10:18,947,371-18,947,395) and 
ARL5B minor (5’-GACATTCAATTTCGTTTCATGCCAG-3’; chr10:18,947,371-
18,947,395). 1 ug nuclear extract was incubated with 1 ng dsDNA probe for 30 min at 
21°C in buffer consisting of 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM DTT, 1 mM 
EDTA and 12.5% glycerol (Sigma-Aldrich). 1 ug antibody was added for super-shift 




CRISPR conversion of rs11080327 was performed as described (69). Briefly, a guide 
sequence (5’-CACCGCCCATGAGACAGACAGATT-3’; or 5’-CACCGAGACAGACA 
GATTAGGAAT-3’ in independent line) directed to cleave the rs11080327 genomic 
locus was cloned into the Cas9-containing plasmid, PX330. The guide sequence-




TTCAGTGTGATAACATCCTGTGTCA-3’) – used as the template for repair to edit 
rs11080327A/G to rs11080327G/G – were transfected into HEK293T cells using 
Lipofectamine LTX (Life Technologies). Cells were stimulated with 1000 U/mL 
recombinant IFNβ for 6.5 h, and then lysed in RLT buffer supplemented with 1% β -









Identification and population analysis of cis-eQTLs 
As described in the main text, we identified 264 cis-eQTLs. To assess the sharing of 
eQTLs between conditions, we used a meta-analysis to find 173 genes with cis-eQTLs in 
resting, 215 in LPS-stimulated, 217 in influenza-stimulated and 200 in IFNβ-stimulated 
MoDCs (fig. S3C; P-value < 5x10–5; permutation FDR 0.04-0.05). In total, 29% of cis-
eQTL associations were identified in stimulated but not in resting cells (M-value > 0.9).  
 
Since the cohort consisted of three human populations, we assessed whether any cis-
eQTLs were common or specific to these populations. First, to determine whether our 
cis-eQTLs replicated across populations, we used a meta-analysis with variants imputed 
for each population to find an average of 96% of cis-eQTLs (P < 1x10–7; permutation 
test, FDR < 4x10–4) detected in at least two populations (M-value > 0.9; table S5), 
suggesting a high level of replication within our study. Second, we identified 121 genes 
differentially expressed between populations in at least one condition, of which ~50% 
have significant cis-eQTLs (table S5). Since differences in gene expression between 
human populations are believed to be predominantly due to minor allele frequency 
(MAF) differences between populations (70), we identified the subset of genes that 
exhibit significant population differences in gene expression and MAF (PST; P < 0.05; 
FST, P < 0.05) (fig. S3F). Among the 10 identified genes, IFITM3 was associated with a 
variant (rs7944394) found in much higher frequency in Caucasians (MAF 0.44 EUR, 0.1 
AFR and 0 ASI; FST = 0.30; F test, P < 0.05) with the minor allele associated with 
reduced IFITM3 expression (fig. S3G). Consistent with significant variation (F test, P < 
0.05) in allele frequency across human populations, this anti-viral effector gene has been 
proposed to be subject to positive selection (71, 72). 
 
Most genes with cis-reQTLs have baseline eQTLs 
We note that since 81 of the 121 genes with cis-reQTLs also had significant cis-eQTLs in 
baseline (table S4), most of the cis-reQTLs do not arise from an increase in expression or 
power in stimulation conditions. In agreement, we did not detect a strong bias in our 
ability to detect cis-reQTLs based on the magnitude of absolute expression or differential 
expression (fig. S3H). Thus, reQTLs like arise from gene-by-environment interactions. 
 
Identification of multiple cis-eQTLs in TEC locus 
Expression variation of the protein tyrosine kinase gene, TEC, illustrates the regulatory 
complexity of these loci. In the TEC locus, we detected the 3’ SNP rs10938526 and the 5’ 
SNP rs2271173 (conditioned on rs10938526) as two independent cis-eQTLs with 
additive effects (fig. S3D): the variant at the 3’ end (rs2271173) is a cis-eQTL associated 
with baseline expression while the variant at the 5’ end (rs10938526) is a cis-eQTL 
associated with TEC expression in the LPS and influenza conditions but not in the 
baseline nor IFNβ conditions (fig. S3B). Thus, the presence of multiple cis-eQTLs per 
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Fig. S1. A strategy to identify gene-by-environment interactions in the innate 
immune responses of primary human dendritic cells. (A) Anti-CD14 and anti-CD16 
FACS plots showing purity of purified CD14+CD16lo monocytes vs. PBMCs. (B) 
Heatmap of gene expression (log2(nCounts)) of 96 genes (pilot Nanostring gene set) from 
MoDCs pooled from 5 donors and left unstimulated or stimulated with LPS or infected 
with influenza virus over a titration curve. Concentrations indicated with arrows were 
selected for subsequent assays. (C) Heatmap of microarray expression from MoDCs 
(pooled from 13 donors) stimulated over a detailed timecourse with FLU (0, 1, 3, 5, 6, 8, 
10, 12.5 and 20 h) or LPS (0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 20 h). Right: mean expression 
(y-axis; LPS, green; FLU, purple) and standard deviation (error bar) at each time point 






LPS- and FLU-downregulated clusters. Time points where FLU response (10 h) and LPS 
response (5 h) plateau are highlighted and were used for subsequent assays. (D) 
Expression (log2(expression)) of 415 reporter genes in MoDCs prepared from two 
different vials of the same PBMC source to estimate the technical reproducibility of the 
assay. Monocytes from the two samples were separately isolated, differentiated into 
MoDCs, and left unstimulated or stimulated with LPS or FLU. Gene expression was 
measured by microarray, expression or induction of the two samples was plotted, and R2 
was calculated. For comparison, expression of resting MoDCs vs. of LPS-stimulated 
MoDCs is shown in inset in blue, and expression of resting MoDCs vs. of FLU-infected 
MoDCs is shown in inset in red. (E) Anti-CD14 and anti-CD16 FACS data from the 
initial 30 donors and 12 replicate samples (top) for the microarray study, and from the 
subsequent 534 donors and 37 replicate samples (bottom) for the Nanostring study. (F) 
Pie charts showing the 1506 samples as well as 92 replicate samples (total 1598 samples) 
separated by condition and ethnicity of individuals; black, resting; blue, LPS; red, FLU; 


























Fig. S2. Genome-wide expression profiles in MoDCs reveal response phenotypes. (A) 
Volcano plots showing differentially expressed genes in MoDCs, from 30 individuals, 
stimulated with LPS for 5 h or FLU for 10 h. The mean log2(fold change, 
stimulated/unstimulated) in expression of each gene (x-axis) is plotted against the –
log10(P-value) testing significance of fold change (y-axis). Genes showing log2(fold 
change) greater than 0.75 or less than –1.5 are shown as colored dots (blue, LPS-
stimulated; red, FLU-stimulated). Selected genes are labeled. (B) Log2(fold change) of 
CLEC4F in LPS-stimulated and FLU-infected MoDCs from 30 donors and 12 replicates. 
Standard error of replicate samples is shown for each sample. Fold change of CLEC4F 
shows significant (FDR < 0.01) inter- vs. intra-individual variation following LPS and 
FLU stimulations. (C) LPS-induced (left) and FLU-induced (right) fold changes of 
Nanostring reporter genes are plotted against fold changes of respective genes from 
microarray. (D) Ground truth Pearson correlation coefficient (gtPCC) (y-axis) plotted 
against number of genes selected for codeset (x-axis), showing that most of the variance 
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Fig. S3. Association analysis reveals cis-eQTLs and cis-reQTLs. (A) Manhattan plot 
of cis-eQTLs in baseline, LPS-, FLU- and IFN -stimulated MoDCs, showing log10(P-
values) (left y-axis) and R2 values (right y-axis) for all cis-SNPs, displayed on the x-axis 
with associated genes ordered by chromosomal location. (B) Box-whisker plots showing 
expression (log2(nCounts)) of DCBLD1, IFNA21, TEC, ARL5B, SLFN5 and CLEC4F in 
resting, LPS-stimulated, FLU-infected and IFN -stimulated MoDCs as a function of 
genotype of the respective cis-SNPs (x-axis: rs27434, rs10964871, rs10938526, 
rs11015435, rs11867191 and rs2075221). African-Americans, Asians, and Europeans in 
this order are displayed as separate box-whisker plots adjacent to each other in each 
condition. (C) Venn diagrams showing overlap of cis-eQTLs between stimulation 
conditions determined by meta-analysis and M-value (M-value > 0.9 used as inclusion 






axis) in the chromosomal regions (x-axis) of TEC before (top) and after (bottom) 
conditioning on the five most significant SNPs in each region. Independent signals were 
seen in in TEC after LPS but not IFN  stimulation. (E) Histogram of cis-eQTL effect 
sizes of regulators (red) and targets (blue), showing that effect sizes of regulators are 
lower than effect sizes of targets. (F) PST plotted against FST, highlighting genes with 
significant expression differences between populations. Purple dots represent genes with 
significant (P < 0.05) PST and FST values. (G) Expression (log2(nCounts); y-axis) of 
IFITM3 in resting, LPS-stimulated, FLU-infected and IFN -stimulated MoDCs as a 
function of genotype of rs7944394, showing that IFITM3 exhibits a population-specific 
cis-eQTL due to different MAFs between populations. African-Americans, Asians, and 
Europeans are displayed as separate box-whisker plots adjacent to each other in each 
condition. (H) R2 as a function of expression (left) and differential expression (right), 
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wt HEK293 [log2(IFNβ/baseline)] 
Fig. S4. Functional fine-mapping and mechanism of cis-reQTLs. (A) Electrophoretic 
mobility shift assays (EMSA) with 27 bp radiolabelled dsDNA probe containing a known 
ISRE motif control incubated with nuclear lysates from IFN -stimulated MoDCs. 
Competition assays were performed with 100-fold excess of cold probes corresponding to 
the ISRE motif control, a mutated ISRE motif control, the CLEC4F rs35856355 major 
(G) or minor allele (T) sequences, or the ARL5B rs2130531 major (G) or minor allele (A) 
sequences. (B) Luciferase expression from reporter constructs transfected into HEK-293 
cells that were left unstimulated or were stimulated with 1000 U/mL IFN  for 21 h. 159 
bp sequence from wt CLEC4F reporter construct, or CLEC4F reporter constructs with 
single point mutations along ISRE motif, were subcloned 5’ of a minimal promoter and 
firefly luciferase gene. Firefly luciferase expression was normalized to Renilla luciferase 
**
expression expressed from co-transfected plasmid. Mean and s.d. are graphed. (C) 5.8 kb 
(chr17:33,568,021-33,573,886) surrounding rs11080327 – a region containing an 
H3K27Ac signal from ENCODE – was sequenced in both wild type and CRISPR-
converted lines, and no differences except for rs11080327 were detected. To further 
confirm the results, an alternative guide sequence was used to create an independent 
CRISPR-converted line: fold change log2(IFN  stim / unstim) of signature genes in wild 
type HEK-293 cells (rs11080327A/G) is plotted against fold change in CRISPR-converted 



















































Fig. S5. Autoimmune and infectious disease-associated SNPs are cis-eQTLs and cis-
reQTLs. (A) Evidence for enrichment of cell-type-specific expression of genes near 
GWAS hits in resting and stimulated dendritic cells, relative to 248 immune cell types in 
the ImmGen database. Each bar represents the empirical P-value for a single cell type, 
colored by cell type groupings. The dashed line is a Bonferroni-corrected significance 
threshold for the number of cell types tested. (B) Ranking of GWAS diseases by the 
hypergeometric P-value of enrichment for variants in close proximity to induced genes 
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Table S1. Donors and samples used in study. Description of samples used in 
microarray and Nanostring experiments including demographic information of donors, 
cell counts, cell purity, annotation of serial replicates, and stimulation conditions.   
 
Table S2. Differential expression analysis of microarray data after LPS and FLU 
stimulation. Differential expression results from analysis using Empirical Bayes (limma 
package) is reported with –log(fold change), –log(P-value) and –log(FDR) after LPS or 
FLU stimulation. 
 
Table S3. Gene signature set. List and annotation of 415-gene signature set used for 
Nanostring gene expression profiles, including gene names, probe sequences, sources 
from how they were selected, FDR values for inter-individual and inter-population 
variability, and mean expression values. 
 
Table S4. cis-eQTLs and cis-reQTLs from pooling three populations together using 
only tagging SNPs. The best tag cis SNP associated with the absolute expression or 
differential expression for each gene in each condition is reported, including effect size 
estimates, coefficient of determination, T statistic, point-wise P-value/FDR and 
permutation P-value/FDR. Also included is a meta-analysis on the absolute expression or 
differential expression over all conditions to determine effects that are shared across 
stimuli. 
 
Table S5. Gene-wise cis-eQTLs from meta-analysis across populations after 
imputation. The best meta-analysis associated cis-eQTL for the absolute or differential 
expression of each gene in each condition is reported with fixed model and random 
model estimates for effect size, standard error, I squared, Cochran Q, meta-analysis P-
value, population specific P-values and M-values. 
 
Table S6. Conditioning analysis of cis-eQTLs from pooling three populations 
together using only tagging SNPs. The second best tag cis SNP associated with the 
absolute expression or differential expression for each gene in each condition is reported 
including effect size estimates, coefficient of determination, T statistic, point-wise P-
value/FDR and permutation P-value/FDR. 
 
Table S7. ChIP-Seq enrichment of top 5 associated imputed SNPs for each gene. 
Enrichment calculated as fold change over background and the respective binomial P-
value for each condition. 
 
Table S8. Trans-eQTLs and trans-reQTLs from pooled analysis (all variants). The 
best meta-analysis associated trans-eQTL for the absolute or differential expression of 
each gene in each condition is reported with fixed model and random model estimates for 
effect size, standard error, I squared, Cochran Q, meta-analysis P-value, population 







Table S9. Trans-eQTLs and trans-reQTLs from pooled analysis (only cis variants 
considered). The best meta-analysis associated trans-eQTL, when considering only the 
set of SNPs cis to at least one gene on our gene signature set, for the absolute or 
differential expression of each gene in each condition is reported with fixed model and 
random model estimates for effect size, standard error, I squared, Cochran Q, meta-
analysis P-value, population specific P-values and M-values. 
 
Table S10. Trans association of rs12805435. Association statistics of rs12805435 to 
gene expression in each condition. 
 
Table S11. GWAS enrichment. Overlap of GWAS variants with cis-eQTLs, with 
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